Switzerland-based CARBOGEN AMCIS AG, a pharmaceutical process development and active pharmaceutical ingredient (API) manufacturing company, announced the renewal of cGMP certificates, and the successful completion of Swissmedic inspections at three of its sites.
Swissmedic conducted inspections (general surveillance audits) of three of CARBOGEN AMCIS’ facilities – Bubendorf, Aarau and Neuland – in late April and early May, 2017. No significant concerns were discovered during the inspections, which resulted in the renewal of the GMP-certificates, granted for all three sites.
“The successful inspections of the Bubendorf, Aarau and Neuland facilities reinforce our commitment to the highest quality standard in Switzerland and worldwide,” said Martin Schneider, Chief Quality Officer at CARBOGEN AMCIS.
“The three facilities meet all expectations related to cGMP and quality for API development and manufacturing services to support our customers. We are extremely pleased to continue our longstanding track record of successful inspections and regulatory audits.”
“Our company is continuously growing and expanding its operations, particularly at our facilities in Bubendorf, Aarau and Neuland. A positive audit is a critical component of our expansion process. We remain deeply committed to excellence, so quality is crucial to our success and our customer’s satisfaction,” said Mark Griffiths, CEO, Dishman Group.